Alexandra Bayer Wildberger
Postdoctoral AssociateDownloadHi-Res Photo
About
Copy Link
Titles
Postdoctoral Associate
Appointments
Neurology
Postdoctoral AssociatePrimary
Other Departments & Organizations
Education & Training
- Postdoctoral Fellow
- Yale Univeristy School of Medicine (2026)
- PhD
- Sorbonne Université, Immunology & Cellular Therapy (2022)
- MSc
- Sorbonne Université, Molecular and Cellular Biology (2018)
- BSc (Hon)
- Universidad Católica “Nuestra Señora de la Asunción”, Medical Biochemistry (2014)
Research
Copy Link
Research at a Glance
Yale Co-Authors
Frequent collaborators of Alexandra Bayer Wildberger's published research.
Publications Timeline
A big-picture view of Alexandra Bayer Wildberger's research output by year.
Kevin C O'Connor, PhD
Richard Nowak, MD, MS
Gianvito Masi, MD
Akiko Iwasaki, PhD
Kenneth Hoehn
Former YSM
9Publications
132Citations
Publications
2025
IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology
Masi G, Chen K, Bayer A, Bayarri-Olmos R, Pham M, Wallace A, Falso S, Evoli A, Iorio R, Hoehn K, Iwasaki A, Nowak R, O’Connor K. IgA autoantibodies demonstrate a novel mechanism of MuSK myasthenia gravis pathology. Brain 2025, 149: awaf410. PMID: 41147199, PMCID: PMC13005154, DOI: 10.1093/brain/awaf410.Peer-Reviewed Original ResearchThis study investigates the role of IgA antibodies in MuSK myasthenia gravis, showing they coexist with IgG4 antibodies, exhibit unique pathogenic potential, and can resist B-cell depletion therapy.Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology
Bayer A, Sanmarco L, Pellerin A, Masi G, Plasencia A, Anderson J, Nowak R, Damato V, Massacesi L, Pham M, Khani-Habibabadi F, Vital H, Higginson-Scott N, Otipoby K, Xing Y, Mascanfroni I, O’Connor K. Therapeutic IgG- and IgM-specific proteases disarm the acetylcholine receptor autoantibodies that drive myasthenia gravis pathology. Proceedings Of The National Academy Of Sciences Of The United States Of America 2025, 122: e2505984122. PMID: 41118207, PMCID: PMC12582293, DOI: 10.1073/pnas.2505984122.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMyasthenia gravisComplement depositionLive cell-based assayComplement activationTherapeutic potentialAcetylcholine receptor autoantibodiesPathogenic effectsReceptor autoantibodiesAChR autoantibodiesAutoantibody-mediated pathologyAutoimmune disordersPatient cohortIgG autoantibodiesEffector functionsPatient stratificationMuscle weaknessPersonalized therapySerum IgGAutoantibodiesPatientsReceptor bindingAcetylcholine receptorsIgGSerum samplesCell-based assaysMesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis
Bayer A, Pinzón N, You A, Bergman C, Dragin N, Corneau A, Truffault F, Noël D, Martinaud C, Le Panse R, Berrih-Aknin S, Vilquin J. Mesenchymal stromal cells conditioned by peripheral blood mononuclear cells exert enhanced immunomodulation capacities and alleviate a model of Myasthenia Gravis. Stem Cell Research & Therapy 2025, 16: 437. PMID: 40781689, PMCID: PMC12333171, DOI: 10.1186/s13287-025-04534-9.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPeripheral blood mononuclear cellsModel of myasthenia gravisHumanized mouse modelBlood mononuclear cellsMyasthenia gravisIFN-gMononuclear cellsMouse model of myasthenia gravisProportions of lymphocyte populationsT cell proliferation in vitroStromal cellsAnimal modelsAnimal model of myasthenia gravisPeripheral blood mononuclear cell subsetsTherapeutic potentialInterferon (IFN)-gBackgroundMesenchymal stromal cellsProliferation in vitroCell-based therapiesAnti-viral responseMass cytometry analysisEfficacy in vivoWeeks post-injectionMesenchymal stromal cellsNFkB signaling pathwayContribution of cellular immune dysregulation to myasthenia gravis pathology
Bayer A, Nowak R, O'Connor K. Contribution of cellular immune dysregulation to myasthenia gravis pathology. International Review Of Neurobiology 2025, 182: 43-66. PMID: 40675740, DOI: 10.1016/bs.irn.2025.04.035.ChaptersCitationsConceptsMyasthenia gravisPersistence of autoimmunityB cell compartmentAbnormal immune responseDevelopment of TResponse to treatmentCellular compartmentsImpaired neuromuscular transmissionImmunopathology of MGTolerance checkpointsComplex immunopathologyImmune dysregulationPrevent autoimmunityT cellsAutoantibody productionPathological responseAutoimmune disordersB cellsDisease developmentAutoimmune diseasesDisease progressionImmune responseMultifactorial diseaseImmune systemNeuromuscular transmission
2024
Respuesta inmunitaria al SARS-CoV-2 previa a la vacunacin en personal de salud de Alto Paran, Paraguay, un estudio seroepidemiolgico
Correa A, Coronel N, Bayer A, Mereles E, Samudio M, Ayala A, Santacruz L, Ojeda M, Espinola I, Jorgge R. Respuesta inmunitaria al SARS-CoV-2 previa a la vacunacin en personal de salud de Alto Paran, Paraguay, un estudio seroepidemiolgico. Revista Chilena De Infectología 2024, 41: 239-247. DOI: 10.4067/s0716-10182024000200239.Peer-Reviewed Original Research
2020
The authors reply: Comment on: "Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients" by Etienne et al.
Etienne J, Joanne P, Catelain C, Riveron S, Bayer Wildberger A, Lafable J, Punzon I, Blot S, Agbulut O, Vilquin J. The authors reply: Comment on: "Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients" by Etienne et al. Journal Of Cachexia, Sarcopenia And Muscle 2020, 11 DOI: 10.1002/jcsm.12629.Peer-Reviewed Original ResearchAldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients
Etienne J, Joanne P, Catelain C, Riveron S, Bayer A, Lafable J, Punzon I, Blot S, Agbulut O, Vilquin J. Aldehyde dehydrogenases contribute to skeletal muscle homeostasis in healthy, aging, and Duchenne muscular dystrophy patients. Journal Of Cachexia Sarcopenia And Muscle 2020, 11: 1047-1069. PMID: 32157826, PMCID: PMC7432589, DOI: 10.1002/jcsm.12557.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsDuchenne muscular dystrophyDuchenne muscular dystrophy patientsHealthy non-human primatesMuscle cell populationsAldehyde dehydrogenase activityCell populationsDMD muscle tissuesPopulation of ALDH-positive cellsMuscular dystrophyFlow cytometryContext of muscular dystrophyMarkers of stem cellsNon-human primatesIn vitroMuscular dystrophy patientsALDH-positive cellsSkeletal muscle homeostasisAldehyde dehydrogenaseDystrophic individualsPhenotypic characterizationCell therapySkeletal muscle physiologyDystrophy patientsAldefluorAnatomical localization
2019
The Muscle Is Not a Passive Target in Myasthenia Gravis
Vilquin J, Bayer A, Le Panse R, Berrih-Aknin S. The Muscle Is Not a Passive Target in Myasthenia Gravis. Frontiers In Neurology 2019, 10: 1343. PMID: 31920954, PMCID: PMC6930907, DOI: 10.3389/fneur.2019.01343.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricConceptsMyasthenia gravisDefective immune regulationPassive targetingRare autoimmune diseaseCombination of genetic predispositionNeuromuscular junctionAnti-AChR antibodiesSevere side effectsChronic cell activationMG diseasePathogenic antibodiesAnti-AChRMyasthenic patientsAutoimmune attackAutoimmune diseasesPathophysiological mechanismsGenetic predispositionSymptomatic treatmentImmune regulationCell activationLife-threateningSide effectsRespiratory musclesSoluble factorsPathogenic mechanisms
2018
Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis
Villegas J, Bayer A, Ider K, Bismuth J, Truffault F, Roussin R, Santelmo N, Le Panse R, Berrih-Aknin S, Dragin N. Il-23/Th17 cell pathway: A promising target to alleviate thymic inflammation maintenance in myasthenia gravis. Journal Of Autoimmunity 2018, 98: 59-73. PMID: 30578016, DOI: 10.1016/j.jaut.2018.11.005.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsIL-23/TH17 pathwayEctopic germinal centersMyasthenia gravis patientsIL-23/Th17Th17 cellsInterleukin-23Interleukin-17Germinal centersMyasthenia gravisAutoimmune diseasesInterferon type I pathwayThymus of MG patientsProduction of auto-antibodiesCell pathwaysProduction of interleukin-23Cell developmentHigher secretionAutoimmune myasthenia gravisB cell maturationTh17 cell developmentExpression of cytokinesChronic autoimmune diseaseMG patientsAuto-antibodiesB cells
Academic Achievements & Community Involvement
Copy Link
Honors
honor Next Generation Research Grant in Myasthenia Gravis
07/01/2026National AwardAmerican Brain Foundation & American Academy of Neurologyhonor The Myasthenia Gravis Rare Disease Network (MGNet) Scholar Award
01/01/2025National AwardThe Myasthenia Gravis Rare Disease Network (MGNet)
News
Copy Link
News
Get In Touch
Copy Link
Contacts
Locations
O'Connor Lab
Lab
300 George Street, Fl 3rd Floor, Rm 325B
New Haven, CT 06511